Core Viewpoint - 招银国际 has raised the target price for WuXi AppTec (02268) from HKD 74 to HKD 88, maintaining a "Buy" rating, anticipating significant revenue and profit growth from 2025 to 2027 [1] Group 1: Financial Projections - Revenue is expected to grow by 45.7%, 36.6%, and 31.7% year-on-year for the years 2025, 2026, and 2027 respectively [1] - Adjusted net profit is projected to increase by 34.9%, 38.4%, and 32.9% for the same years [1] - The above forecasts do not account for the impact of the acquisition of Easton Pharmaceuticals-B (01875) [1] Group 2: Earnings Announcement - WuXi AppTec has issued a positive earnings forecast, expecting at least a 45% year-on-year revenue growth and over 38% net profit growth for 2025 [1] - Adjusted net profit is anticipated to grow by over 45%, with a potential increase exceeding 65% when excluding foreign exchange effects [1] Group 3: Project Development - The company is set to achieve a record of 70 new comprehensive projects in 2025, representing a 32% year-on-year increase [1] - The number of Process Performance Qualification (PPQ) projects is expected to surge by 125% to 18, indicating strong commercial production potential [1] Group 4: Strategic Acquisition - To address the increasing customer demand, the company has announced a cash offer to acquire at least 60% of Easton Pharmaceuticals, marking a strategic move to enhance production capacity [1]

Core Viewpoint - 招银国际 has raised the target price for WuXi AppTec (02268) from HKD 74 to HKD 88, maintaining a "Buy" rating, with projected revenue growth of 45.7%, 36.6%, and 31.7% for 2025 to 2027, respectively, and adjusted net profit growth of 34.9%, 38.4%, and 32.9% [1] Group 1: Financial Projections - WuXi AppTec has issued a positive earnings forecast, expecting at least 45% revenue growth and over 38% net profit growth in 2025, with adjusted net profit anticipated to grow by over 45%, and over 65% when excluding foreign exchange impacts [1] - The company is projected to achieve a record 70 new comprehensive projects in 2025, representing a 32% year-on-year increase [1] - The number of Process Performance Qualification (PPQ) projects is expected to surge by 125% to 18, indicating strong commercial production potential [1] Group 2: Strategic Developments - To address the increasing customer demand, WuXi AppTec has announced a cash offer to acquire a 60% stake in Easton Pharmaceuticals-B (01875), marking a significant step in enhancing its production capabilities [1]

Group 1 - The core viewpoint of the reports is that various companies are expected to show significant growth in revenue and profitability, with specific targets set by different securities firms [1][2][3][4][5][6][7][8][9] Group 2 - WuXi AppTec (药明合联) is projected to achieve a 45% revenue growth and a 38% net profit growth by 2025, with a record of 70 new integrated projects and a 125% increase in contracts at the PPQ stage [1] - Alibaba (阿里巴巴-SW) is enhancing its ecosystem with the integration of the Q&A app into various platforms, aiming to capture AI-driven traffic and commercial opportunities [1] - Budweiser APAC (百威亚太) is expected to face pressure in China but maintain competitive advantages in Korea and strong sales in high-end products in India, with a mild recovery anticipated in 2026 [2] - Gu Ming (古茗) plans to expand into northern regions and is optimistic about same-store sales, with successful product launches in coffee and breakfast items [3] - Haidilao (海底捞) is focusing on operational efficiency and service quality improvements through new brand incubations and innovative business models [4] - China Resources Beverage (华润饮料) is expected to recover by 2026 after a period of channel reform, with a stable market share in packaged water [5] - J&T Express (极兔速递-W) is enhancing its logistics capabilities through a partnership with SF Express, which will improve cross-border delivery and local fulfillment [6] - Li Ning (李宁) is seeing a narrowing decline in revenue and is expected to improve brand strength through increased marketing investments in the Olympic year [7] - 361 Degrees (361度) is achieving a 10% year-on-year growth in offline sales and exceeding its store opening targets, with a focus on enhancing brand image [8] - Luk Fook Holdings (六福集团) reported a 26% year-on-year increase in retail value, with a 15% increase in same-store sales, benefiting from product structure optimization and favorable tax policies [9]

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Core Viewpoint - Daiwa reports that WuXi Biologics (02269) and WuXi AppTec (02268) plan to make a full acquisition offer for at least 60% of the shares of Easton Biopharma (01875) for a maximum cost of approximately 2.8 billion yuan, with the expectation that Easton Biopharma will maintain its listing status after the acquisition [1] Group 1 - The acquisition is expected to help WuXi AppTec expand its business and gain additional operational production capacity in China [1] - The deal aims to enrich the project portfolio and expand the customer base for WuXi AppTec [1] - This acquisition is anticipated to strengthen WuXi AppTec's leading market position in the ADC contract research and manufacturing organization sector [1] Group 2 - Daiwa currently assigns a "Buy" investment rating to WuXi Biologics [1]

Group 1 - The core viewpoint of the article is that WuXi Biologics (02269) and WuXi AppTec (02268) have announced a comprehensive acquisition offer to acquire at least 60% of the shares of Easton Biopharma (01875) for a maximum price of approximately 2.8 billion yuan [1] - The acquisition is expected to help WuXi AppTec expand its business and gain additional operational production capacity in China, further enriching its project portfolio and expanding its customer base [1] - The acquisition is anticipated to solidify WuXi AppTec's leading market position in the field of ADC contract research and manufacturing organizations [1] Group 2 - Daiwa currently gives a "Buy" investment rating for WuXi Biologics [1]

Core Viewpoint - Dongning Bio has submitted its listing application for the third time, aiming to provide comprehensive solutions in the life sciences sector, focusing on bioprocessing and laboratory products and services [1][3]. Financial Performance - Revenue for Dongning Bio during the reporting periods (2023 to 2025) was 814.08 million yuan, 842.88 million yuan, and 657.75 million yuan, respectively, with profits of -315 million yuan, -27.5 million yuan, and 14.26 million yuan, indicating a recent turnaround to profitability [3][4]. - The bioprocessing solutions segment accounted for 77% of total revenue in 2023, with reagents and consumables being the primary revenue driver, contributing 44.1%, 47%, and 55.4% in respective periods [3][4]. Business Segments - The company operates two main business lines: bioprocessing solutions and laboratory products and services, with the former being the larger contributor to revenue [1][3]. - The overseas revenue doubled in the first three quarters of 2025, rising from 53.8 million yuan to 112.41 million yuan, increasing its share of total revenue from 9.8% to 17.1% [5][6]. Major Clients and Shareholders - WuXi Biologics, a major shareholder with a 19.75% stake, is also the largest client, contributing 14.9%, 10.9%, and 12.1% of total revenue during the reporting periods [8][10]. - Revenue from the top five clients accounted for 31.1%, 23.9%, and 32.0% of total revenue, indicating a reliance on a concentrated client base [8]. Acquisitions and Goodwill - Since 2020, Dongning Bio has acquired several companies in the bioprocessing and laboratory services sector, leading to a goodwill value of 843 million yuan as of September 30, 2025, which may face impairment risks [10][11]. - The company must estimate future cash flows from acquired subsidiaries to assess goodwill impairment, which could negatively impact financial conditions if assumptions are not met [13].

Core Viewpoint - WuXi AppTec is expected to report significant revenue and profit growth, with a projected revenue increase of at least 45% and a net profit growth of over 38% by 2025, indicating strong business performance and market demand [1] Group 1: Financial Projections - The adjusted net profit is anticipated to grow by over 45%, and if excluding foreign exchange impacts, the growth could exceed 65% [1] - Revenue growth projections for 2025 to 2027 are 45.7%, 36.6%, and 31.7% respectively, while adjusted net profit growth is forecasted at 34.9%, 38.4%, and 32.9% [1] Group 2: Business Development - The company is set to achieve a record of 70 new comprehensive projects in 2025, representing a year-on-year growth of 32% [1] - The number of Process Performance Qualification (PPQ) projects is expected to surge by 125% to 18, highlighting strong commercial production potential [1] Group 3: Strategic Moves - To address increasing customer demand, the company announced a cash offer to acquire at least 60% of Easton Pharmaceuticals, which signifies a strategic enhancement of its production capabilities [1] Group 4: Analyst Rating - The target price for WuXi AppTec has been raised from HKD 74 to HKD 88, with a maintained "Buy" rating [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights that the performance of leading CXO companies is impressive, with significant growth expected in 2025. Notable companies such as WuXi AppTec, WuXi Biologics, and CRDMO are projected to see substantial revenue increases, with WuXi AppTec's revenue expected to grow by approximately 21.4% year-on-year, and net profit expected to increase by 102.7% [3][12] - The demand side is gradually improving, with the global healthcare industry expected to see a total investment of $63.882 billion in 2025, reflecting a year-on-year growth of 10.13%. The domestic market in China is also showing signs of recovery, with total financing in the healthcare sector expected to reach 73.777 billion yuan, a year-on-year increase of 39.05% [4][18] Summary by Sections Section 1: Performance of Leading CXO Companies - The report indicates that leading CXO companies are expected to continue their strong performance into 2025, with significant revenue and profit growth anticipated. WuXi AppTec is expected to achieve a revenue of approximately 45.456 billion yuan, with a year-on-year growth of 21.4% and a net profit increase of 102.65% [12][13] - WuXi Biologics is projected to benefit from the ADC sector, with revenue growth exceeding 45% and gross profit growth over 70% [3][12] - CRDMO is also expected to see a revenue increase of 13% to 16%, with net profit growth of 36% to 41% [14] Section 2: Demand Side Improvement - The global healthcare investment is expected to reach $63.882 billion in 2025, with a notable recovery in the second half of the year, showing a year-on-year increase of 10.13% [4][18] - In China, the total financing in the healthcare sector is projected to reach 73.777 billion yuan, marking a 39.05% year-on-year increase, with a significant rise in new drug IND applications [18][19] - The report notes that the average R&D investment among the top 30 global pharmaceutical companies is expected to grow steadily, with an average of $4.172 billion in the first three quarters of 2025, reflecting a year-on-year increase of 3.45% [4][20] Section 3: Market Trends - In the second week of January 2026, the pharmaceutical and biotechnology sector saw a decline of 0.68%, underperforming the CSI 300 index by 0.11 percentage points [5][24] - The medical R&D outsourcing sector experienced the highest growth, with an increase of 3.69%, while the vaccine sector faced the largest decline, dropping by 3.43% [5][25] - The report also highlights that the clinical CRO sector is expected to see a significant improvement in performance, with companies like Tigermed and Proprius maintaining steady growth in both revenue and orders [23]